Kaminski N E, Holsapple M P
Dept. of Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298.
Immunopharmacology. 1992 Nov-Dec;24(3):229-40. doi: 10.1016/0162-3109(92)90078-q.
We have previously reported that subcutaneous injection of casein, a potent inducer of the immunomodulatory acute phases reactant, serum amyloid A (SAA) protein, produces a marked suppression of humoral responses that require macrophage accessory cell cooperativity in the B6C3F1 mouse. The objective of these studies was to further characterize the immunological changes produced by casein treatment. It was observed that the inhibition of the sRBC IgM AFC response which accompanies casein treatment is dose related to the amount of casein introduced subcutaneously to the mouse. These studies, as well as those previously reported by several laboratories including our own have demonstrated that spleen cells isolated from casein-treated mice also exhibit markedly suppressed humoral responses in vitro. However, casein added directly to naive spleen cell cultures at concentrations significantly higher than those which would be found in the lymphoid tissues of the intact animal have no direct inhibitory effect on the sRBC IgM AFC response, suggesting that casein alone does not exert a direct immunosuppressive effect. Kinetics of recovery studies indicate that the casein-induced immunosuppression is readily reversible. Humoral responses are fully recovered within 3 days, once subcutaneous injections of casein are terminated. In vitro measurements of IL-1 secretion following stimulation of splenic macrophages, isolated from casein treated mice, with lipopolysaccharide indicate no significant effect on the capacity of these cells to produce this cytokine. Direct addition of recombinant IL-1 or interferon-gamma to spleen cell cultures isolated from casein-treated mice also was found to be incapable of reversing the inhibited IgM AFC response. Taken together, these studies strongly suggest that the accessory cell dysfunction associated with macrophages from casein-treated mice is not due to the inability of these cells to secrete IL-1 and indicate that the dysfunction cannot be reversed by IL-1 or interferon-gamma. Casein treatment was also found to markedly inhibit DTH, a cell-mediated immune response requiring macrophage accessory cell function. interestingly, the DTH responses were only affected by casein when it was administered post-sensitization with antigen (sRBC) but prior to antigen challenge. When casein was administered prior to sensitization with antigen, which is analogous to the treatment schedule that was found to suppress the sRBC antibody response, no effect was observed on DTH.
我们之前报道过,皮下注射酪蛋白(一种免疫调节急性期反应物血清淀粉样蛋白A,即SAA蛋白的强效诱导剂)会显著抑制B6C3F1小鼠中需要巨噬细胞辅助细胞协同作用的体液免疫反应。这些研究的目的是进一步描述酪蛋白处理所产生的免疫变化。据观察,酪蛋白处理伴随的对绵羊红细胞IgM抗体形成细胞(AFC)反应的抑制与皮下注射给小鼠的酪蛋白量呈剂量相关。这些研究以及包括我们自己实验室在内的几个实验室之前报道的研究均表明,从经酪蛋白处理的小鼠中分离出的脾细胞在体外也表现出明显受抑制的体液免疫反应。然而,以明显高于完整动物淋巴组织中浓度的酪蛋白直接添加到未接触过抗原的脾细胞培养物中,对绵羊红细胞IgM AFC反应没有直接抑制作用,这表明单独的酪蛋白不会产生直接的免疫抑制作用。恢复动力学研究表明,酪蛋白诱导的免疫抑制很容易逆转。一旦停止皮下注射酪蛋白,体液免疫反应在3天内完全恢复。用脂多糖刺激从经酪蛋白处理的小鼠中分离出的脾巨噬细胞后,对这些细胞产生这种细胞因子的能力进行体外测量,结果表明没有显著影响。向从经酪蛋白处理的小鼠中分离出的脾细胞培养物中直接添加重组白细胞介素-1(IL-1)或干扰素-γ也无法逆转受抑制的IgM AFC反应。综上所述,这些研究强烈表明,与经酪蛋白处理的小鼠的巨噬细胞相关的辅助细胞功能障碍并非由于这些细胞无法分泌IL-1,并且表明这种功能障碍不能被IL-1或干扰素-γ逆转。还发现酪蛋白处理会显著抑制迟发型超敏反应(DTH),这是一种需要巨噬细胞辅助细胞功能的细胞介导免疫反应。有趣的是,DTH反应仅在致敏后(用抗原即绵羊红细胞致敏)但在抗原攻击前给予酪蛋白时受到影响。当在抗原致敏前给予酪蛋白时(这类似于被发现抑制绵羊红细胞抗体反应的处理方案),未观察到对DTH有影响。